Patent applications published 20 January 2010
Merck 2144503*
- Hydromethyl ether hydroisoindoline tachykinin receptor antagonists
Merck 2144503*
- Method of treating brain cancer
Myriad Pharmaceuticals 2144504*
- 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
Cortex Pharmaceuticals; Les Laboratoires Servier 2144506*
- Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
The Trustees of the University of Pennsylvania 2144507*
- Alpha-galactosyl ceramide analogues and their use as immunotherapies
Academia Sinica 2144594*
- Novel compsns containing lysozyme and C-1/C04 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynaecology
Saint Simeon 2144596*
- Oil-in-water emulsions IIwhich are stabilised by their active ingredient
Henkel 2144597*
- Precipitation sterilising compsns
University of Strathclyde 2144598*
- Sustained release pellets comprising wax-like material
Farnam Companies 2144599*
- Poly (amino acid)targeting moieties
Massachusetts Institute of Technology; The Brigham and Women's Hospital 2144600*
- Rapidly dissolving pharmaceutical compsns comprising pullulan
University of Kansas 2144601*
- Use of iron chelator for the treatment of myocardial infarction
Novartis 2144602*
- Use of a monoterpene to treat or prevent stress
Aisa Therapeutics 2144603*
- Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP)inhibitors
Conatus Pharmaceuticals 2144604*
- sGC stimulators, sGC activators and combinations for the treatment of urological disorders
Bayer HealthCare 2144605*
- Remedy for the treatment of cardio-vascular diseases or disorders
Max-Delbrueck-Centrum fuer Molekulare Medizin 2144606*
- Methods and compsns for contributing to the treatment of cancers
Spectrum Pharmaceuticals; The Board of Trustees of the University of Illinois 2144607*
- Pharmaceutical formulations containing lipoic acid derivatives
Cornerstone Pharmaceuticals 2144609*
- Melatonin tablet and methods of preparation and use
McCarty, John 2144610*
- Anti-tumour activity of temsirolimus in papillary renal cell cancer
Wyeth 2144611*
- Methods and compsns for treating diseases and conditions associated with mitochondrial function
The Regents of the University of Michigan 2144612*
- Method of altering bone growth by administration of SOSTor WISEantagonist or agonist
Osteogenex 2144613*
- Methods for treating spinal muscular atrophy using tetracycline compounds
Paratek Pharmaceuticals 2144614*
- Methods of use of gamma inhibitor compounds for the attenuation of pain
Kai Pharmaceuticals 2144615*
- Use of hyperbaric conditions to provide neuroprotection
Air Products and Chemicals 2144616*
- Delivery of flu antibodies to surfaces in contact with air
Immuron 2144617*
- Bioaffective krill oil compsns
Aker Biomarine 2144618*
- Novel uses of hibiscus, in particular pharmaceutical uses
Burgundy 2144619*
- Novel method for preparing purified extracts of harpagophytum procumbens
Burgundy 2144620*
- Guava extract
Omnica 2144621*
- Calcium flux as pharmacoefficacy biomarker for inhibitors of histone deacetylase
Pharmacyclics 2144622*
- Process for the manufacture of a dairy-based anti-inflammatory compsn
Advitech 2144623*
- Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
Stryker Corp 2144624*
- A controlled release enzymatic compsn and methods of use
Arcimboldo 2144625*
- Tuberculosis vaccine and method of using same
Lighter, Jennifer; Fisher, Jason 2144626*
- Compsn containing HCMVparticles
Vakzine Projekt Management; Rhein Biotech 2144627*
- Cysteine engineering anti-Muc16 antibodies and antibody drug conjugates
Genentech 2144628*
- Method for stabilising a protein
F Hoffmann-La Roche 2144629*
- CHK1 inhibitors with Bcell depleting antibodies for the treatment of haematologic malignancies
AstraZeneca 2144630*
- Multifunctional polyglutamate drug carriers
Nitto Denko 2144631*
- Synthetic herpes simplex viruses type-1 for treatment of cancers
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College 2144632*
- A system for delivering therapeutic agents into living cells and cells nuclei
Segev Laboratories 2144633*
- Methods for synthesising and purifying aminoalkyl tetracycline compounds
Paratek Pharmaceuticals 2144870*
- Amidation process for the preparation of cathepsin K inhibitors
Merck Frosst Canada 2144871*
- Low calcemic, highly antiproliferative, analogues of calcitrol
Johns Hopkins University 2144872*
- High shear process for the production of cumene hydroperoxide
HRD Corp 2144873*
- 5-lipoxygenase-activating protein (FLAP) inhibitors
Amira Pharmaceuticals 2144874*
- 5-lipoxygenase-activating protein (FLAP) inhibitors
Amira Pharmaceuticals 2144875*
- Oxime ester photoinitiators
BASF 2144876*
- Novel pyridine derivatives, processes for preparing them, pharmaceutical compsns thereof
UCBPharma 2144877*
- N-heterocyclic compounds useful as inhibitors of janus kinases
Vertex Pharmaceuticals 2144878*
- Isoquinolinone derivatives, processes for their preparation an their use in the treatment of chronic obstructive pulmonary disease (COPD) and asthma
AstraZeneca 2144881*
- Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
Sanofi-Aventis 2144885*
- Method of treating melanoma
Myriad Pharmaceuticals 2144886*
- Dosages and methods for the treatment of cancer
Myriad Pharmaceuticals 2144887*
- Methods for treating cancer
Myriad Pharmaceuticals 2144888*
- Quinazolin-oxime derivatives as HSP90 inhibitors
DAC 2144889*
- Method for preparing halogenated amines
Wyeth 2144890*
- 5-oxo-isoxazoles as inhibitors of lipases and phospholipases
Sanofi-Aventis 2144891*
- Improved process for preparing quetiapine fumarate
Teva Pharmaceutical Industries 2144892*
- Tricyclic compounds as matrix metalloproteinase inhibitors
Wyeth 2144893*
- Oxime ester photoinitiators
BASF 2144894*
- Isoquinolinecarboxamides as inhibitors of stearoyl-CoA desaturase
SmithKline Beecham 2144895*
- Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical compsn comprising same
Hanmi Pharma 2144896*
- 8-oxy-quinoline derivatives as bradykinin B2 receptor modulator
Jerini 2144897*
- Epoxy compound and method for manufacturing the same
Otsuka Pharmaceutical 2144899*
- Oxime ester photoinitiators
BASF 2144900*
- Oligothiophene derivatives
Universite Libre de Bruxelles; Universite de Mons-Hainaut 2144901*
- [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
Bristol-Myers Squibb 2144902*
- Substituted deuterium enriched thiophenes for the treatment of hypertension
Auspex Pharmaceuticals 2144903*
- (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide and use thereof an anti-cancer and antiviral agent
Ganial Immunotherapies 2144904*
- Therapeutic agents
Merck 2144905*
- Heterocycles as orexin antagonists
FHoffmann-La Roche 2144906*
- Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
Santhera Pharmaceuticals 2144907*
- 2,6-napthyridine derivatives as protein kinase modulators
Novartis 2144908*
- 2,6-naphthyridiens useful ads protein kinase inhibitors
Novartis 2144909*
- Oxazolidinone antibiotics
Actelion Pharmaceuticals 2144910*
- Purinyl derivatives and their use as potassium channel modulators
NeuroSearch 2144911*
- 18 F-labelled folates
Merck Eprova 2144912*
- Substituted tetrahydropyrrolopyrazine compounds as monoamine reuptake inhibitors
Gruenenthal 2144913*
- Prano-pyrazole-amines
Laboratoires Del Dr Esteve 2144914*
- Spiro-pyrano-pyrazole derivatives
Laboratoires Del Dr Esteve 2144915*
- Phen-naphthalene and phen-quinoline derivatives and their use for binding and imaging amyloid plaques
The Trustees of the University of Pennsylvania 2144916*
- 1-aza-3,7-dioxabicylco[3.3.0.]octane compounds and monocyclic oxazolidines from pro-fragrances
Henkel 2144917*
- Functionalised nanoparticles
BASF 2144918*
- Multi-step synthesis of ibandronate
FHoffmann-La Roche 2144919*
- Novel compounds
Diosamine Development 2144920*